JRJorge Toquero Ramos

Jorge Toquero Ramos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jorge Toquero Ramos has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors of Success in Fractured Electrode Extraction: The Impact of Fracture Location and Access Strategies

    by Jorge Balaguer German, Victor Castro Urda, Jorge Toquero Ramos, Daniel E. Brenes Solano, Ignacio Fernandez Lozano

    Introduction: Fractured or sheared cardiac implantable electronic device leads presents a unique clinical challenge in transvenous lead extraction. These cases are associated with clinical failure rates of up to 40% and a greater likelihood of retained fragments. The aim of this study was to characterize fractured lead extractions performed at a referral center and identify predictors of complete removal and clinical success. Methods: We conducted a retrospective single center study including all consecutive patients who underwent TLE for electrodes fractured before or during extraction between October 2011 and December 2025. Clinical, echocardiographic, and procedural data were collected. Results: A total of 46 procedures were analyzed. Mean age was 62.7 years and median lead dwell time was 9.0 years. The most frequent fracture site was the electrode body (67.4%). A rotational mechanical sheath was used in 84.8% of cases (39/46), and femoral snaring was used in 60.8%. Complete extraction occurred in 32.6% whereas clinical success was achieved in 80.4% of patients. Retained fragments > 4 cm were observed in 28.3%. In multivariate analysis, the use of a 13Fr sheath was independently associated with lower odds of clinical success ( p = 0.011). Fracture location was the only consistent independent predictor of complete extraction ( p = 0.031). Femoral access showed a favorable trend but did not reach statistical significance after adjustment. Conclusions: In fractured lead extraction, fracture location is the strongest predictor of complete removal, surpassing clinical and procedural variables. These findings highlight the importance of preoperative planning and suggest that femoral access may play a key role in selected complex cases.

  • Open Access

    Vascular access and closure management for electrophysiological interventions in 2025: a Clinical Consensus Statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Surgery

    by Tom J R De Potter, Chiara Valeriano, Finn Akerstrom, Salvatore Cassese, Malcolm Finlay, Dhiraj Gupta, Josef Kautzner, Antonio Miceli, Sotirios Nedios, Katarzyna Malaczynska-Rajpold, et al.

    Graphical Abstract A standardized step-by-step approach to vascular access during electrophysiological procedures: Begin by identifying patients at higher risk for vascular complications and consider alternative access routes in cases of inferior vena cava interruption. Allow the patient to drink clear fluids and adopt an uninterrupted anticoagulation strategy when feasible. Choose the access site based on procedural needs and patient anatomy, giving preference to ultrasound-guided puncture to improve accuracy and reduce complications. At the end of the procedure, select the most appropriate closure technique – manual compression, figure-of-eight suture, or a vascular closure device – based on access site, sheath size, and patient-specific factors.


  • Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial

    by Víctor Castro-Urda, Melodie Segura-Dominguez, Diego Jiménez-Sánchez, Cristina Aguilera-Agudo, Paula Vela-Martín, Alvaro Lorente-Ros, Daniel García-Rodriguez, David Sánchez-Ortiz, Chinh Pham-Trung, Eusebio García-Izquierdo, et al.

    BACKGROUND: Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development. METHODS: We investigated the efficacy and safety of combining cryoballoon pulmonary vein isolation (PVI) with SVC ablation compared with PVI alone in 100 patients with paroxysmal or non–long-standing persistent atrial fibrillation. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. Each patient was given a mobile device to record a daily ECG and detect atrial tachyarrhythmias. RESULTS: The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 days post-catheter ablation, did not significantly differ between the 2 groups (62.9% versus 72%; P =0.41). However, the PVI+SVC group exhibited higher rates of phrenic nerve paralysis (20.8% versus 6%; P =0.003) and transient sinus node injury (18.8% versus 0%; P =0.001) compared with the PVI-only group. The median burden of atrial tachyarrhythmia showed no significant difference ( P =0.91). CONCLUSIONS: The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. These findings do not support the routine inclusion of SVC ablation in cryoballoon procedures for first-time catheter ablation in patients with paroxysmal or non–long-standing persistent atrial fibrillation.


  • Open Access

    Right Bundle Branch Block Predicts Appropriate Implantable Cardioverter Defibrillator Therapies in Patients with Non-Ischemic Dilated Cardiomyopathy and a Prophylactic Implantable Cardioverter Defibrillator

    by Marta Jiménez-Blanco Bravo, Gonzalo Luis Alonso Salinas, Carolina Parra Esteban, Jorge Toquero Ramos, Miguel Amores Luque, Jose Luis Zamorano Gómez, Eusebio García-Izquierdo, Jesús Álvarez-García, Ignacio Fernández Lozano, Víctor Castro Urda

    Background: The benefit of prophylactic implantable cardioverter defibrillators (ICDs) in patients with severe systolic dysfunction of non-ischemic origin is still unclear, and the identification of patients at risk for sudden cardiac death remains a major challenge. Aims/Methods: We retrospectively reviewed all consecutive patients with non-ischemic dilated cardiomyopathy (NICM) who underwent prophylactic ICD implantation between 2008 and 2020 in two tertiary centers. Our main goal was to identify the predictors of appropriate ICD therapies (anti-tachycardia pacing [ATP] and/or shocks) in this cohort of patients. Results: A total of 224 patients were included. After a median follow-up of 51 months, 61 patients (27.2%) required appropriate ICD therapies. Patients with appropriate ICD therapies were more frequently men (87% vs. 69%, p = 0.006), of younger age (59 years, (53–65) vs. 64 years, (57–70); p = 0.02), showed more right bundle branch blocks (RBBBs) (15% vs. 4%, p = 0.007) and less left bundle branch blocks (LBBBs) (26% vs. 47%, p = 0.005) in the ECG, and had higher left ventricular end-diastolic (100 mL/m2, (90–117) vs. 86, (71–110); p = 0.011) and systolic volumes (72 mL/m2, (59–87) vs. 61, (47–81), p = 0.05). In a multivariate competing-risks regression analysis, RBBB (HR 2.26, CI 95% 1.02–4.98, p = 0.043) was identified as an independent predictor of appropriate ICD therapies. Conclusion: RBBBs may help to identify patients with NICM at high risk of ventricular arrhythmias and requiring ICD intervention.


  • Open Access

    Repeat cryoablation as a redo procedure for atrial fibrillation ablation: Is it a good choice?

    by Carlos Antonio Álvarez-Ortega, César Rainer Solórzano Guillén, Alberto Barrera Cordero, Jorge Enrique Toquero Ramos, Jesús Daniel Martínez-Alday, Carlos Eugenio Grande Morales, Aníbal Rodríguez González, Arcadio García Alberola, Luisa Pérez Álvarez, Ángel Ferrero de Loma Osorio, et al.

    Background: Ablation of atrial fibrillation (AF), both cryoablation ablation (CBA) and radiofrequency catheter ablation (RFCA), have demonstrated to be safe and effective. About 1 in 3 patients may face a redo due to recurrence and the best technique is unknown. The aim of this study is to assess the efficacy of CBA as a repeat procedure in patients with prior CBA or RFCA. Methods: A nation-wide CBA registry (RECABA) was analyzed and patients were compared who had previously undergone CBA (Prior-CB) or RFCA (Prior-RF). The primary endpoint was AF recurrence at 12 months after a 3-month blanking period. A survival analysis was performed, univariate and multivariate Cox models were also built. Results: Seventy-four patients were included. Thirty-three (44.6%) were in the Prior-CB group and 41 (55.4%) in the Prior-RF. There were more reconnected pulmonary veins in the Prior-RF than in Prior-CB group (40.4% vs.16.5%, p = 0.0001). The 12-month Kaplan–Meier estimate of freedom from AF recurrence after the blanking period was 61.0% (95% confidence interval [CI] 41.4–75.8%) in the Prior-CB, and 89.2% (95% CI 73.6–95.9%) in the Prior-RF group (p = 0.002). Multivariate Cox regression pointed Prior-CB as the sole independent predictor of AF recurrence, with an adjusted HR of 2.67 (95% CI 1.05–6.79). Conclusions: Repeat CBA shows higher rates of AF recurrences compared to CBA after a previous RFCA despite presenting less reconnected veins at the procedure. These data suggest that patients with AF recurrence after CBA may benefit from other ablation techniques after a recurrence. RECABA is registered at clinicaltrials.gov with the Unique Identifier NCT02785991. Background: Ablation of atrial fibrillation (AF), both cryoablation ablation (CBA) and radiofrequency catheter ablation (RFCA), have demonstrated to be safe and effective. About 1 in 3 patients may face a redo due to recurrence and the best technique is unknown. The aim of this study is to assess the efficacy of CBA as a repeat procedure in patients with prior CBA or RFCA. Methods: A nation-wide CBA registry (RECABA) was analyzed and patients were compared who had previously undergone CBA (Prior-CB) or RFCA (Prior-RF). The primary endpoint was AF recurrence at 12 months after a 3-month blanking period. A survival analysis was performed, univariate and multivariate Cox models were also built. Results: Seventy-four patients were included. Thirty-three (44.6%) were in the Prior-CB group and 41 (55.4%) in the Prior-RF. There were more reconnected pulmonary veins in the Prior-RF than in Prior-CB group (40.4% vs.16.5%, p = 0.0001). The 12-month Kaplan–Meier estimate of freedom from AF recurrence after the blanking period was 61.0% (95% confidence interval [CI] 41.4–75.8%) in the Prior-CB, and 89.2% (95% CI 73.6–95.9%) in the Prior-RF group (p = 0.002). Multivariate Cox regression pointed Prior-CB as the sole independent predictor of AF recurrence, with an adjusted HR of 2.67 (95% CI 1.05–6.79). Conclusions: Repeat CBA shows higher rates of AF recurrences compared to CBA after a previous RFCA despite presenting less reconnected veins at the procedure. These data suggest that patients with AF recurrence after CBA may benefit from other ablation techniques after a recurrence. RECABA is registered at clinicaltrials.gov with the Unique Identifier NCT02785991.


  • Open Access

    The Right Atrial Area as a New Factor to Predict Successful Pulmonary Vein Isolation: an Emergent Predictor Variable

    by Cristina Aguilera Agudo, Victor Castro Urda, Jorge Toquero Ramos, Diego Jiménez Sánchez, Darwin Veloza Urrea, Eusebio García-Izquierdo Jaén, Chinh Pham Trung, Vanesa Moñivas Palomero, Susana Mingo Santos, Ignacio Fernández Lozano

    Up to now, few factors have been identified to predict successful pulmonary vein isolation, none of which with high predictive values. The objective of our study was to compare different predictive factors of atrial fibrillation recurrence after pulmonary vein isolation,including new parameters of the right atrium (area and index volume). We retrospectively analysed data from 66 patients and included echocardiogram parameters performed within 18 months prior to the ablation procedure. We excluded patients with left ventricular dysfunction (defined as a left ventricular ejection fraction < 50%); previous diagnostic of cardiomyopathy; severe valvular heart disease; severe pulmonary hypertension; or those with poor image quality in the echocardiogram. We considered atrial fibrillation recurrence to be the presence of atrial fibrillation of 30 seconds or longer demonstrated by a standard electrocardiogram or in a 24-hour Holter electrocardiogram within a year after the ablation procedure. We found that the right atrium area (odds ratio = 1.52; 95% confidence interval 0.95–2.43, P = 0.08) and a previous pulmonary vein isolation procedure (odds ratio = 0.21; 95% confidence interval 0.04–1.01, P = 0.05) were nearly statistically significant predictors of successful atrial fibrillation ablation at one year. Although our study was limited because of a low number of patients and because it is a retrospective analysis, we found that a higher right atrial area may be related to the late recurrence of atrial fibrillation. This tendency may be useful in predicting patient outcomes.


  • Open Access

    Zfhx3 Transcription Factor Represses the Expression of SCN5A Gene and Decreases Sodium Current Density (INa)

    by Marcos Rubio-Alarcón, Anabel Cámara-Checa, María Dago, Teresa Crespo-García, Paloma Nieto-Marín, María Marín, José Luis Merino, Jorge Toquero, Rafael Salguero-Bodes, Juan Tamargo, et al.

    The ZFHX3 and SCN5A genes encode the zinc finger homeobox 3 (Zfhx3) transcription factor (TF) and the human cardiac Na+ channel (Nav1.5), respectively. The effects of Zfhx3 on the expression of the Nav1.5 channel, and in cardiac excitability, are currently unknown. Additionally, we identified three Zfhx3 variants in probands diagnosed with familial atrial fibrillation (p.M1260T) and Brugada Syndrome (p.V949I and p.Q2564R). Here, we analyzed the effects of native (WT) and mutated Zfhx3 on Na+ current (INa) recorded in HL-1 cardiomyocytes. ZFHX3 mRNA can be detected in human atrial and ventricular samples. In HL-1 cardiomyocytes, transfection of Zfhx3 strongly reduced peak INa density, while the silencing of endogenous expression augmented it (from −65.9 ± 8.9 to −104.6 ± 10.8 pA/pF; n ≥ 8, p < 0.05). Zfhx3 significantly reduced the transcriptional activity of human SCN5A, PITX2, TBX5, and NKX25 minimal promoters. Consequently, the mRNA and/or protein expression levels of Nav1.5 and Tbx5 were diminished (n ≥ 6, p < 0.05). Zfhx3 also increased the expression of Nedd4-2 ubiquitin-protein ligase, enhancing Nav1.5 proteasomal degradation. p.V949I, p.M1260T, and p.Q2564R Zfhx3 produced similar effects on INa density and time- and voltage-dependent properties in WT. WT Zfhx3 inhibits INa as a result of a direct repressor effect on the SCN5A promoter, the modulation of Tbx5 increasing on the INa, and the increased expression of Nedd4-2. We propose that this TF participates in the control of cardiac excitability in human adult cardiac tissue.


  • Effect of Successful Edge-to-Edge Mitral Valve Repair on Ventricular Arrhythmic Burden in Patients With Functional Mitral Regurgitation and Implantable Cardiac Devices

    by Tomás Benito-González, Rodrigo Estévez-Loureiro, Carmen Garrote-Coloma, Carlos Arellano-Serrano, Elena Tundidor-Sanz, Ignacio Fernández-Lozano, Jorque Toquero, Armando Pérez de Prado, Javier Goicolea, Felipe Fernández-Vázquez